Cognis Group Supports Seoul Bio Hub Portfolio Companies' Technology Commercialization through their Pharmalicensing.com Division
Cognis Group are highlighting 13 innovative technologies from seven different South Korean companies, supported by Seoul Bio Hub, and coordinated by IIDC Global (Korea)
TAMPA, Fla., Dec. 21, 2018 /PRNewswire-PRWeb/ -- The Cognis Group, an international innovation consultancy specializing in Foresight, IP Strategy, and Commercialization services, and their South Korea partners IIDC Global, Inc. (Korea), announce that they are working with Seoul Bio Hub of South Korea to highlight and internationally commercialize 13 innovative technologies from Seoul Bio Hub portfolio companies through Cognis Group's http://www.pharmalicensing.com platform.
Technologies being highlighted include:
Mirajet: A Laser Pulsed Needle-Free Injection System for cosmetic/medical procedures, from JSK Biomed;
Solubilization of insoluble drugs to develop therapeutics or functional foods, from Abtis Antibody Technology;
Use of Digital Nano X-Ray Source in Diagnostic X-Ray Imaging, from CAT Beam Tech; and
Osteo-F, Osteoporosis-targeting new herbal formula for health supplement, from Boin Bio Convergence.
If not already registered to the Pharmalicensing.com service, please register free-of-charge, and then click through the above links to view the innovative opportunities.
Mark McBride, Managing Director of Pharmalicensing & VP Technology Marketplaces for Cognis Group commented "We are delighted to be working with Seoul Bio Hub to help commercialize these important technologies from their portfolio companies, and appreciate the faith shown in us by Seoul Bio Hub as a unique route to the global lifescience marketplace."
James Noh, CEO of IIDC Global Inc. said, "I am happy that we have been able to bring Seoul Bio Hub and Cognis Pharmalicensing together, and we look forward to working with more of Seoul Bio Hub's portfolio companies in the same way, and other South Korean companies to help them raise their international profiles and find commercialization partners."
About Cognis Group
Cognis Group, founded in 1997 as IP Technology Exchange, is an international research firm specializing in future-proofing company technology innovation pipelines. Their unique methodology overlays future trends with current IP strategy and marketplace analytics, resulting in actionable insights to make the best-informed decisions around innovation potential. In addition, their partnering services provide a global network of licensing connections and the negotiation tools to make faster, smarter deals along the commercialization path. Cognis offers broad access to experts across an expansive number of science & tech industries, making them a full-service partner for clients ranging from Fortune 500 companies, to research universities and federal institutions, to individual inventors. https://cognisgroup.com
About Pharmalicensing
Pharmalicensing.com, a Cognis Group company, showcases more than 23,000 life science technologies and thousands of companies and organizations spanning 110 countries. Whether scouting for technologies or marketing your own, Pharmalicensing helps to accelerate technology licensing and acquisition of novel technologies. http://www.pharmalicensing.com
About IIDC Global Inc (Korea)
IIDC Global is Cognis Group's exclusive partner in South Korea. IIDC Global is a consulting firm specializing in consulting services in the field of IP (Intellectual Property), Biopharma, and Renewable Energy. In the area of technology transfer, they provide optimal in-and-out licensing technology commercialization services by linking various networks established with overseas organizations and companies.
About Seoul Bio Hub
Seoul Bio Hub is directly run and managed by the Korea Health Industry Development Institute (KHIDI) with rich experiences and know-how in the biomedical industry both in Korea and internationally. Seoul Bio Hub features a wide range of international and domestic biomedical specialists who work as evaluators and advisors in their fields including intellectual property, commercialization, research, and clinical trial. http://www.seoulbiohub.kr
SOURCE Cognis Group
Share this article